智通财经APP获悉,和黄医药(00013)涨超3%,截至发稿,涨3.7%,报29.45港元,成交额8500.17万港元。
消息面上,和黄医药宣布,因FRUZAQLA®(呋喹替尼) 用于治疗转移性结直肠癌的销售额超过2亿美元触发,将收到来自合作伙伴武田 (TSE: 4502/ NYSE: TAK) 的2千万美元里程碑付款。截至2024年9月的九个月内,武田实现 FRUZAQLA® 净销售额2.03亿美元。
和黄医药首席执行官兼首席科学官苏慰国博士表示,此次收到2000万美元里程碑付款将进一步巩固公司的资产负债表,期待扩展呋喹替尼用于更多新的适应症,以及在更广泛的管线中推动公司的全球合作战略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.